ESR1 and breast cancer: Although over 50% of ESR1-positive patients show response to endocrine therapy and estrogen deprivation therapy reduces BC mortality by 40%3, a large proportion relapse with de novo or acquired resistant disease, making it one of the greatest challenges for BC research and treatment.